152 related articles for article (PubMed ID: 27758824)
1. CK2 inhibitor CX-4945 destabilizes NOTCH1 and synergizes with JQ1 against human T-acute lymphoblastic leukemic cells.
Lian H; Li D; Zhou Y; Landesman-Bollag E; Zhang G; Anderson NM; Tang KC; Roderick JE; Kelliher MA; Seldin DC; Fu H; Feng H
Haematologica; 2017 Jan; 102(1):e17-e21. PubMed ID: 27758824
[No Abstract] [Full Text] [Related]
2. Regulation of PTEN by CK2 and Notch1 in primary T-cell acute lymphoblastic leukemia: rationale for combined use of CK2- and gamma-secretase inhibitors.
Silva A; Jotta PY; Silveira AB; Ribeiro D; Brandalise SR; Yunes JA; Barata JT
Haematologica; 2010 Apr; 95(4):674-8. PubMed ID: 20015880
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling.
Buontempo F; Orsini E; Martins LR; Antunes I; Lonetti A; Chiarini F; Tabellini G; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; McCubrey JA; Cappellini A; Barata JT; Martelli AM
Leukemia; 2014 Mar; 28(3):543-53. PubMed ID: 24253024
[TBL] [Abstract][Full Text] [Related]
4. Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB.
Buontempo F; Orsini E; Lonetti A; Cappellini A; Chiarini F; Evangelisti C; Evangelisti C; Melchionda F; Pession A; Bertaina A; Locatelli F; Bertacchini J; Neri LM; McCubrey JA; Martelli AM
Oncotarget; 2016 Jan; 7(2):1323-40. PubMed ID: 26593250
[TBL] [Abstract][Full Text] [Related]
5. Transcriptional Regulation of PIK3CD and PIKFYVE in T-Cell Acute Lymphoblastic Leukemia by IKAROS and Protein Kinase CK2.
Dovat E; Song C; Hu T; Rahman MA; Dhanyamraju PK; Klink M; Bogush D; Soliman M; Kane S; McGrath M; Ding Y; Desai D; Sharma A; Gowda C
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467550
[TBL] [Abstract][Full Text] [Related]
6. Synergistic therapeutic effect of diethylstilbestrol and CX-4945 in human acute T-lymphocytic leukemia cells.
Jung JI; Park KY; Kim SA; Kim J
Biomed Pharmacother; 2018 Feb; 98():357-363. PubMed ID: 29275177
[TBL] [Abstract][Full Text] [Related]
7. Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia.
Peirs S; Frismantas V; Matthijssens F; Van Loocke W; Pieters T; Vandamme N; Lintermans B; Dobay MP; Berx G; Poppe B; Goossens S; Bornhauser BC; Bourquin JP; Van Vlierberghe P
Leukemia; 2017 Oct; 31(10):2037-2047. PubMed ID: 28074072
[TBL] [Abstract][Full Text] [Related]
8. An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia.
Knoechel B; Roderick JE; Williamson KE; Zhu J; Lohr JG; Cotton MJ; Gillespie SM; Fernandez D; Ku M; Wang H; Piccioni F; Silver SJ; Jain M; Pearson D; Kluk MJ; Ott CJ; Shultz LD; Brehm MA; Greiner DL; Gutierrez A; Stegmaier K; Kung AL; Root DE; Bradner JE; Aster JC; Kelliher MA; Bernstein BE
Nat Genet; 2014 Apr; 46(4):364-70. PubMed ID: 24584072
[TBL] [Abstract][Full Text] [Related]
9. Combined Casein Kinase II inhibition and epigenetic modulation in acute B-lymphoblastic leukemia.
Richter A; Roolf C; Hamed M; Gladbach YS; Sender S; Konkolefski C; Knübel G; Sekora A; Fuellen G; Vollmar B; Murua Escobar H; Junghanss C
BMC Cancer; 2019 Mar; 19(1):202. PubMed ID: 30841886
[TBL] [Abstract][Full Text] [Related]
10. In vitro combinatorial anti-proliferative and immunosuppressive effects of Brucea javanica extract with CX-4945 and imatinib in human T-cell acute lymphoblastic leukemia cells.
Jung JI; Kim SY; Park KY; Sydara K; Lee SW; Kim SA; Kim J
Biomed Pharmacother; 2018 Oct; 106():403-410. PubMed ID: 29966986
[TBL] [Abstract][Full Text] [Related]
11. T-cell acute lymphoblastic leukemias express a unique truncated FAT1 isoform that cooperates with NOTCH1 in leukemia development.
de Bock CE; Down M; Baidya K; Sweron B; Boyd AW; Fiers M; Burns GF; Molloy TJ; Lock RB; Soulier J; Taghon T; Van Vlierberghe P; Cools J; Holst J; Thorne RF
Haematologica; 2019 May; 104(5):e204-e207. PubMed ID: 30514801
[No Abstract] [Full Text] [Related]
12. Simultaneous Inhibition of Protein Kinase CK2 and Dihydrofolate Reductase Results in Synergistic Effect on Acute Lymphoblastic Leukemia Cells.
Wińska P; Widło Ł; Skierka K; Krzyśko A; Koronkiewicz M; Cieśla JM; Cieśla J; Bretner M
Anticancer Res; 2019 Jul; 39(7):3531-3542. PubMed ID: 31262877
[TBL] [Abstract][Full Text] [Related]
13. An activating intragenic deletion in NOTCH1 in human T-ALL.
Haydu JE; De Keersmaecker K; Duff MK; Paietta E; Racevskis J; Wiernik PH; Rowe JM; Ferrando A
Blood; 2012 May; 119(22):5211-4. PubMed ID: 22510873
[TBL] [Abstract][Full Text] [Related]
14. CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death.
Mandato E; Nunes SC; Zaffino F; Casellato A; Macaccaro P; Tubi LQ; Visentin A; Trentin L; Semenzato G; Piazza F
Curr Cancer Drug Targets; 2018; 18(6):608-616. PubMed ID: 28460620
[TBL] [Abstract][Full Text] [Related]
15. A CK2-dependent mechanism for degradation of the PML tumor suppressor.
Scaglioni PP; Yung TM; Cai LF; Erdjument-Bromage H; Kaufman AJ; Singh B; Teruya-Feldstein J; Tempst P; Pandolfi PP
Cell; 2006 Jul; 126(2):269-83. PubMed ID: 16873060
[TBL] [Abstract][Full Text] [Related]
16. T-ALL: ALL a matter of Translation?
Girardi T; De Keersmaecker K
Haematologica; 2015 Mar; 100(3):293-5. PubMed ID: 25740104
[No Abstract] [Full Text] [Related]
17. The Genetics and Mechanisms of T-Cell Acute Lymphoblastic Leukemia.
Gianni F; Belver L; Ferrando A
Cold Spring Harb Perspect Med; 2020 Mar; 10(3):. PubMed ID: 31570389
[TBL] [Abstract][Full Text] [Related]
18. Targeting NOTCH1 in T-ALL: Starving the dragon.
Herranz D; Ferrando AA
Cell Cycle; 2016; 15(4):483-4. PubMed ID: 26864725
[No Abstract] [Full Text] [Related]
19. CX-4945, a selective inhibitor of casein kinase-2 (CK2), exhibits anti-tumor activity in hematologic malignancies including enhanced activity in chronic lymphocytic leukemia when combined with fludarabine and inhibitors of the B-cell receptor pathway.
Prins RC; Burke RT; Tyner JW; Druker BJ; Loriaux MM; Spurgeon SE
Leukemia; 2013 Oct; 27(10):2094-6. PubMed ID: 23900138
[No Abstract] [Full Text] [Related]
20. In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia.
De Keersmaecker K; Lahortiga I; Mentens N; Folens C; Van Neste L; Bekaert S; Vandenberghe P; Odero MD; Marynen P; Cools J
Haematologica; 2008 Apr; 93(4):533-42. PubMed ID: 18322257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
